Promising pancreatic cancer combo trial halted early

NCT ID NCT04390763

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the experimental drugs NIS793 (with or without spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial enrolled 164 adults and aimed to see if the combinations slowed cancer growth better than chemo alone. However, the study was terminated early, so final results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Cente

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Novartis Investigative Site

Westmead, New South Wales, 2145, Australia
Novartis Investigative Site

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site

Salzburg, 5020, Austria
Novartis Investigative Site

Vienna, A-1090, Austria
Novartis Investigative Site

Liège, 4000, Belgium
Novartis Investigative Site

Brno, Czech Republic, 656 53, Czechia
Novartis Investigative Site

Helsinki, FIN-00029, Finland
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Toulouse, 31054, France
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Milan, MI, 20141, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Verona, VR, 37134, Italy
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 168583, Singapore
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08036, Spain
Novartis Investigative Site

Madrid, 28050, Spain
Novartis Investigative Site

Sankt Gallen, 9007, Switzerland
Novartis Investigative Site

Zurich, 8091, Switzerland
Novartis Investigative Site

Taichung, 40447, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Oxford, OX3 7LE, United Kingdom
Sidney Kimmel CCC At JH

Baltimore, Maryland, 21231, United States
Univ of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania, 15232, United States
Winship Cancer Institute

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.